The debate continues, but this time with cystatin-C measurements. Read the #TenTweetNephJC summary here!
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
The debate continues, but this time with cystatin-C measurements. Read the #TenTweetNephJC summary here!
Welcome to #TenTweetNephJC tweetorial
— Nephrology Jrnl Club (@NephJC) September 13, 2022
✳️ 10 tweets to catch-up with #NephJC ✳️
Have you ever prescribed piperacillin-tazobactam? Or avoided it due to fear of causing AKI?
Read on to learn more about the ‘nephrotoxin’ versus ‘pseudonephrotoxin’ debate pic.twitter.com/ZKX1ElhZds